These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35559782)

  • 1. Matrix metalloproteinase inhibitors (MMPIs) as attractive therapeutic targets: Recent progress and current challenges.
    Shi Y; Ma X; Fang G; Tian X; Ge C
    NanoImpact; 2021 Jan; 21():100293. PubMed ID: 35559782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
    Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
    Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in the development of matrix metalloproteinase inhibitors.
    Tu G; Xu W; Huang H; Li S
    Curr Med Chem; 2008; 15(14):1388-95. PubMed ID: 18537616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer.
    Zhong Y; Lu YT; Sun Y; Shi ZH; Li NG; Tang YP; Duan JA
    Expert Opin Drug Discov; 2018 Jan; 13(1):75-87. PubMed ID: 29088927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes.
    Winer A; Adams S; Mignatti P
    Mol Cancer Ther; 2018 Jun; 17(6):1147-1155. PubMed ID: 29735645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
    Yang JS; Lin CW; Su SC; Yang SF
    Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to Target Matrix Metalloproteinases as Therapeutic Approach in Cancer.
    Piperigkou Z; Manou D; Karamanou K; Theocharis AD
    Methods Mol Biol; 2018; 1731():325-348. PubMed ID: 29318564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present).
    Banerjee S; Baidya SK; Adhikari N; Jha T
    Expert Opin Ther Pat; 2023 Oct; 33(10):631-649. PubMed ID: 37982191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting.
    Gialeli C; Theocharis AD; Karamanos NK
    FEBS J; 2011 Jan; 278(1):16-27. PubMed ID: 21087457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.
    Mitsiades N; Poulaki V; Mitsiades CS; Anderson KC
    Expert Opin Investig Drugs; 2001 Jun; 10(6):1075-84. PubMed ID: 11772236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinase inhibitors (MMPIs) from marine natural products: the current situation and future prospects.
    Zhang C; Kim SK
    Mar Drugs; 2009 Mar; 7(2):71-84. PubMed ID: 19597572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects.
    Li W; Saji S; Sato F; Noda M; Toi M
    Int J Biol Markers; 2013 Jun; 28(2):117-30. PubMed ID: 23787494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials.
    Pavlaki M; Zucker S
    Cancer Metastasis Rev; 2003; 22(2-3):177-203. PubMed ID: 12784996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioactives from Marine Organisms and their Potential Role as Matrix Metalloproteinase Inhibitors.
    Thomas NV; Monica Diyya AS; Kim SK; Faraj KA; Ghafoor DD; Qian ZJ; Tigabu BM
    Curr Pharm Des; 2022; 28(41):3351-3362. PubMed ID: 36411577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The past, present and future perspectives of matrix metalloproteinase inhibitors.
    Li K; Tay FR; Yiu CKY
    Pharmacol Ther; 2020 Mar; 207():107465. PubMed ID: 31863819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies.
    Das S; Amin SA; Jha T
    Eur J Med Chem; 2021 Nov; 223():113623. PubMed ID: 34157437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments.
    Lin H; Xu P; Huang M
    Future Med Chem; 2022 Jan; 14(1):35-51. PubMed ID: 34779649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
    Zucker S; Cao J; Chen WT
    Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Imaging Probes Based on Matrix Metalloproteinase Inhibitors (MMPIs).
    Rangasamy L; Geronimo BD; Ortín I; Coderch C; Zapico JM; Ramos A; de Pascual-Teresa B
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31426440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Phenolic Matrix Metalloproteinase Inhibitors by Peptide Microarray for Osteosarcoma Treatment.
    Jian M; Sun X; Cheng G; Zhang H; Li X; Song F; Liu Z; Wang Z
    J Nat Prod; 2022 Oct; 85(10):2424-2432. PubMed ID: 36122348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.